In the CheckMate 648 trial, which evaluated nivolumab combination therapy in advanced esophageal squamous cell carcinoma, the cCR was 13% for the overall population and 16% for those with a tumor-cell PD-L1 expression of 1% or greater. Here, CD274 is linked to neoplasm.